米哚妥林治疗急性髓系白血病的研究进展

Research Progress on Treating Acute Myeloid Leukemia by Midostaurin—— Review

约30%的急性髓系白血病(acute myeloid leukemia,AML)患者携带FLT3基因突变,这与AML的发生、发展及不良预后密切相关,因此针对FLT3突变的靶向治疗可能是治疗AML的新途径。米哚妥林(midostaurin,PKC412)能够抑制FLT3基因编码的Ⅲ型受体酪氨酸激酶的活性,诱导细胞周期阻滞,对具有突变型FLT3、野生型FLT3及表达突变型FLT3受体的AML原始细胞均具有细胞凋亡作用。鉴于此,本文就FLT3突变与AML的关系以及米哚妥林在AML,尤其是具有突变型FLT3基因的AML治疗中的最新研究进展作一综述。

FLT3 gene mutations occurred in approximately 30%of acute myeloid leukemia(AML) patients,which is closely associated with the occurrence,development and poor prognosis of AML.The therapy targeting at FLT3 mutations might be a promising treatment for AML.Midostaurin can inhibit the activities of IH receptor tyrosine kinase encoded by FLT3 gene,induce cell cycle arrest and has a apoptotic effect on primitive AML cells of FLT3-mutant,FLT3wild-type and the expression of FLT3 mutated receptor.In view of this,the association between FLT3 mutations and AML,and research advances and clinical applications of midostaurin on the treatment of AML especially for FLT3 mutated AML,are reviewed.